Abner Herrman & Brock LLC grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 4.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 59,018 shares of the medical research company’s stock after buying an additional 2,505 shares during the quarter. Amgen comprises 2.1% of Abner Herrman & Brock LLC’s portfolio, making the stock its 18th largest holding. Abner Herrman & Brock LLC’s holdings in Amgen were worth $11,489,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Deane Retirement Strategies Inc. lifted its stake in Amgen by 0.6% during the fourth quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock worth $1,915,000 after purchasing an additional 60 shares during the last quarter. Arlington Partners LLC lifted its stake in Amgen by 86.7% during the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the last quarter. Murphy Capital Management Inc. lifted its stake in Amgen by 2.3% during the third quarter. Murphy Capital Management Inc. now owns 11,285 shares of the medical research company’s stock worth $2,339,000 after purchasing an additional 254 shares during the last quarter. Fairfield Bush & CO. lifted its stake in Amgen by 0.8% during the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock worth $6,264,000 after purchasing an additional 260 shares during the last quarter. Finally, Mutual Advisors LLC lifted its stake in Amgen by 5.8% during the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $889,000 after purchasing an additional 265 shares during the last quarter. Institutional investors and hedge funds own 76.88% of the company’s stock.

AMGN stock traded down $3.48 on Friday, reaching $199.20. 111,434 shares of the company’s stock were exchanged, compared to its average volume of 3,032,399. Amgen, Inc. has a twelve month low of $163.31 and a twelve month high of $210.19. The firm has a market capitalization of $127.68 billion, a PE ratio of 15.85, a P/E/G ratio of 2.05 and a beta of 1.32. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. During the same quarter in the prior year, the company posted $3.27 earnings per share. Amgen’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts expect that Amgen, Inc. will post 14.24 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio is currently 41.97%.

Several research analysts have commented on AMGN shares. Citigroup lifted their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Goldman Sachs Group reaffirmed a “buy” rating and set a $221.00 price target on shares of Amgen in a research report on Wednesday, October 31st. Cantor Fitzgerald started coverage on Amgen in a research report on Monday, October 1st. They set a “neutral” rating and a $223.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $220.00 price target on shares of Amgen in a research report on Monday, October 1st. Finally, Royal Bank of Canada reaffirmed a “neutral” rating on shares of Amgen in a research report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $205.90.

In related news, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the transaction, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the sale, the director now owns 28,979 shares in the company, valued at $5,662,786.39. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Abner Herrman & Brock LLC Buys 2,505 Shares of Amgen, Inc. (AMGN)” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/01/11/abner-herrman-brock-llc-buys-2505-shares-of-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Relative Strength Index

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.